Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological treatment option London, UK – 28 July 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in…


Previous articleSilo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
Next articlePsychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company Enters Death Spiral Financing